No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LEGN Legend Biotech
- 46.190
- -0.930-1.97%
Close Apr 19 16:00 ET
- 45.730
- -0.460-1.00%
Post 19:34 ET
8.40BMarket Cap-15710P/E (TTM)
47.300High45.680Low1.25MVolume47.120Open47.120Pre Close58.15MTurnover1.58%Turnover RatioLossP/E (Static)181.91MShares77.32052wk High6.71P/B3.67BFloat Cap45.68052wk Low--Dividend TTM79.38MShs Float77.320Historical High--Div YieldTTM3.44%Amplitude23.410Historical Low46.373Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
Scotiabank Upgrades Legend Biotech to Sector Outperform
Analyst Ratings For Legend Biotech
12 analysts have expressed a variety of opinions on Legend Biotech (NASDAQ:LEGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their
Express News | Scotiabank Upgrades Legend Biotech to Sector Outperform, Maintains Price Target to $65
Express News | Legend Biotech Corp : Scotiabank Raises to Sector Outperform From Sector Perform
Comments
FDA PDUFA Update…
🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
9
1
$Legend Biotech(LEGN.US$
waiting patiently for fda 😌🙏✨
waiting patiently for fda 😌🙏✨
2
FDA PDUFA Update…
🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US$ : 🤔
⇒...
$Akebia Therapeutics(AKBA.US$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US$ : 🤔
⇒...
8
4
PDUFA Calendar-April
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US$$Legend Biotech(LEGN.US$$Supernus Pharmaceuticals(SUPN.US$$ImmunityBio(IBRX.US$$Aquestive Therapeutics(AQST.US$$X4 Pharmaceuticals(XFOR.US$$Liquidia(LQDA.US$$Neurocrine Biosciences(NBIX.US$$Moderna(MRNA.US$$Day One Biopharmaceuticals(DAWN.US$
...
$Vanda Pharmaceuticals(VNDA.US$$Legend Biotech(LEGN.US$$Supernus Pharmaceuticals(SUPN.US$$ImmunityBio(IBRX.US$$Aquestive Therapeutics(AQST.US$$X4 Pharmaceuticals(XFOR.US$$Liquidia(LQDA.US$$Neurocrine Biosciences(NBIX.US$$Moderna(MRNA.US$$Day One Biopharmaceuticals(DAWN.US$
...
21
2
AdCom for CARVYKTI on 3/15
$Legend Biotech(LEGN.US$$Johnson & Johnson(JNJ.US$
⇨ FDA’s briefing docs released today! 🔔
⚠️ Early deaths in cilta-cel arm raise FDA concern despite PFS benefit... 🤔
$LEGN trending up ~6% after doc release 📈
ℹ️ CARVYKTI (ciltacabtagene autoleucel)
⇒ multiple myeloma
⇒ CARTITUDE-4 study
⇒ sBLA
⇒ PDUFA: 4/5/24
❓AdCom Discussion & Question:
Discussion Topic:
⇒ Discuss whether the results of CARTITUDE-4 provided in the supplemental application are sufficient to support a positive...
⇨ FDA’s briefing docs released today! 🔔
⚠️ Early deaths in cilta-cel arm raise FDA concern despite PFS benefit... 🤔
$LEGN trending up ~6% after doc release 📈
ℹ️ CARVYKTI (ciltacabtagene autoleucel)
⇒ multiple myeloma
⇒ CARTITUDE-4 study
⇒ sBLA
⇒ PDUFA: 4/5/24
❓AdCom Discussion & Question:
Discussion Topic:
⇒ Discuss whether the results of CARTITUDE-4 provided in the supplemental application are sufficient to support a positive...
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Ginvest : Thank you for the timely info